Patent Application
20150329867
The invention relates to the effect of caspase-8 activity in the pathology or course of a skin disease, disorder or condition.
Members of the caspase cysteine protease family can be activated by a variety of death inducing agents to cleave a set of death-related cellular proteins and thus initiate programmed cell death (or apoptosis). Different caspases serve distinct roles in this process. Some caspases named “effector caspases” exert most of the cleavage of death-related substrates. Other caspases named “initiator caspases” serve to activate the effector caspases following their own activation by distinct death inducers with which they interact through specific N-terminal recognition sequences. Growing evidence indicates that in various cells, including lymphocytes, hematopoietic progenitors, endothelial cells and others, caspases also participate in vital functions (Kang et al., 2004). So far, there is still very little knowledge of the relative contribution of the different caspases to these non-apoptotic functions or to the mechanisms by which the caspases mediate these non-apoptotic functions. It is not clear what are the mechanisms that define whether caspase activation at a given situation will lead to death or promote vital functions. Some studies suggested that, unlike the induction of death, the non-apoptotic functions of the caspases do not involve their enzymatic function, but rather involves a role of the caspases as adapter proteins or allosteric regulators of other signaling proteins (Chaudhary et al., 2000). In contrast, other studies suggested that the enzymatic activity of the caspases does contribute to their non-apoptotic functions (Hasegawa et al., 2005).
As the body's largest and most environment-exposed surface, the skin has a central role in host defense. The skin consists of three layers: epidermis, dermis and hypodermis. Epidermis, the outermost layer of the skin, is made up of stratified squamous epithelium and is composed of the basal, spinous, granular and cornified layers (Fuchs and Segre, 2000, Lavker and Sun, 2000). The epidermal keratinocytes of the basal layers have the proliferative capacity and constitute a pool of epidermal stem cells. The transient amplifying cells are those stem cells that undergo 3-5 more cycles of division. They are then destined to move upwards from the basal layers to undergo terminal differentiation (Potten, 1981, Adams and Watt, 1990).
The growth and differentiation of keratinocytes is regulated by many growth factors and cytokines including EGF, transforming-growth factor (TGF)-α, heparin binding EGF-like factor (HB-EGF), amphiregulin, keratinocyte growth factor (KGF), TGF-β, insulin-like growth factor, platelet derived growth factor (PDGF), hepatocyte growth factor (HGF), IL-6, IL-1 and TNF-α (Bennett and Schultz, 1993, Peus and Pittelkow, 1996, Martin, 1997).
Atopic dermatitis (AD) is a chronic, inflammatory skin disease that may occur at any age and is very common in children. AD has been reported to affect more than 10% of children and 1-3% of adults.
AD is associated with cutaneous hyper-reactivity to environmental triggers that are innocuous to normal non-atopic individuals. So far, no objective laboratory test for diagnosis of AD exists, and diagnosis is based on clinical observations, which may include pruritus, facial, and extensor eczema in infants and children, flexural eczema in adults, and chronicity of the dermatitis (Leung et al. 2004). Diagnosis of AD is based also on the distribution and duration of lesions and often on a family history of atopic disorders and the presence of lichenification (MERK manual online). Because atopic dermatitis is often hard to differentiate from seborrheic dermatitis in infants or from contact dermatitis at any age, the physician should examine the patient several times before making a definitive diagnosis.
Skin hydration, avoidance of irritants, antihistamines, topical corticosteroids and newer topical immunomodulators are the mainstay of therapy for AD. However, AD is usually refractory to treatment and the local and systemic side effects of topical steroids are widely recognized.
An understanding of the immunologic basis of AD is necessary for the development of novel approaches to treating this disease. AD is associated with diseases and conditions characterized by elevated serum IgE levels and peripheral eosinophilia such as allergic rhinitis, asthma and food allergy and the majority of patients afflicted with AD eventually develop allergic rhinitis or asthma.
A recent review by Leung (2004) summarizes the immunologic characteristics of AD. For example, most AD patients have elevated numbers of circulating eosinophils and increased immunoglobulin E (IgE) levels, which are caused by T-cell dysfunction. An increased frequency of Th2 cells that produce increased IL-4, IL-5 and IL-13 has been demonstrated in the peripheral blood of patients with AD. Factors contributing to Th2 cell development in AD include cytokines, genetic differences in cytokine (IL-4) production, pharmacologic factors (monocytes with increase CAMP phosphodiesterase activity) and antigen presenting cells (increased IgE-bearing Langerhans' cells with a role in cutaneous allergen presentation to Th2 cells).
IL-4 and IL-13 are the only cytokines that promote an increase in IgE production at the level of germline transcription. IL-5 induces eosinophilopoiesis, activation and chemotaxis. Eosinophils secrete cytokines and mediators that injure tissue via reactive O2 intermediates and the release of toxic granule proteins. Eosinophil granule proteins are increased in AD sera and correlate with disease activity.
Psoriasis is a common chronic, recurrent disease characterized by dry, well-circumscribed, silvery, scaling papules and plaques of various sizes (reviewed in the Merk manual online).
Psoriasis varies in severity from one or two lesions to widespread dermatosis, sometimes associated with disabling arthritis or exfoliation. The cause of psoriasis is unknown, but the thick scaling has traditionally been attributed to increased epidermal cell proliferation and concomitant dermal inflammation. The response of psoriasis to the immunosuppressive drug cyclosporine suggests that the primary pathogenetic factor may be immunologic. About 2 to 4% of whites and far fewer blacks are affected. Onset of psoriasis is usually between ages 10 and 40, but no age is exempt. A family history of psoriasis is common
Onset of psoriasis is usually gradual. The typical course is one of chronic remissions and recurrences (or occasionally acute exacerbations) that vary in frequency and duration. Factors precipitating psoriatic flares include local trauma (in the Koebner's phenomenon, lesions appear at sites of trauma) and, occasionally, irritation (variants of Koebner's phenomenon), severe sunburn, viremia, allergic drug reactions, topical and systemic drugs (e.g., chloroquine antimalarial therapy, lithium, -blockers, interferon-), and withdrawal of systemic corticosteroids. Some patients (especially children) may have psoriatic eruptions after an acute group A—hemolytic streptococcal URI.
Psoriasis characteristically involves the scalp (including the postauricular regions), the extensor surface of the extremities (particularly elbows and knees), the sacral area, buttocks, and penis. The nails, eyebrows, axillae, umbilicus, or anogenital region may also be affected. Occasionally the disease is generalized.
Typical lesions are sharply demarcated, variously pruritic, ovoid or circinate erythematous papules or plaques covered with overlapping thick silvery micaceous or slightly opalescent shiny scales. Papules sometimes extend and coalesce to produce large plaques in annular and gyrate patterns, but this phenomenon is more common in cutaneous T-cell lymphoma. The lesions heal without scarring, and hair growth is usually unaltered. Nail involvement occurs in 30 to 50% of patients and may clinically resemble a fungal infection, with stippling, pitting, fraying, discoloration or separation of the distal and lateral margins of the nail plate (onycholysis), and thickening, with hyperkeratotic debris under the nail plate.
Erythrodermic psoriasis (exfoliative psoriatic dermatitis) may be refractory to therapy. The entire cutaneous surface is red and covered with fine scales; typical psoriatic lesions may be obscured or absent. It may lead to general debility and a need for hospitalization.
Pustular psoriasis is characterized by sterile pustules and may be generalized (von Zumbusch type) or localized to the palms and soles (Barber's psoriasis).
Psoriasis may be confused with seborrheic dermatitis, squamous cell carcinoma in situ (Bowen's disease, especially when on the trunk), secondary syphilis, dermatophyte infections, cutaneous lupus erythematosus, eczema, lichen planus, pityriasis rosea, or localized dermatitis caused by scratching (lichen simplex chronicus). However, diagnosis by inspection is rarely difficult; e.g., well-defined, dry, heaped-up psoriatic lesions with large silvery scales are usually distinguishable from the diffuse, greasy, yellowish scaling of seborrheic dermatitis.
Although biopsy findings of typical lesions are generally characteristic, atypical lesions have atypical features making biopsy less helpful; some other skin diseases may have psoriasiform histological features that may make microscopic diagnosis difficult or equivocal.
The prognosis of psoriasis depends on the extent and severity of the initial involvement. Usually the earlier the age of onset, the greater the severity. Acute attacks usually clear, but permanent remission is rare.
The invention relates to the use of an agent selected from (i) caspase-8 or a fragment thereof; (ii) a polynucleotide encoding caspase-8 or a fragment thereof; (iii) an expression vector comprising the polynucleotide of (ii); (iv) an activator of the level or activity of caspase-8; (v) an inhibitor of a natural inhibitor of casapase-8 activation; (vi) an inhibitor of the level or activity of a protein which is normally downregulated by caspase-8 activity in the skin; and (vii) an activator of the level or activity of a protein which is normally upregulated by caspase-8 in the skin, in the manufacture of a medicament for the treatment or prevention of an inflammatory skin disease, disorder or condition.
It is one object of the invention to provide a method of treatment of a skin inflammatory disease, disorder or condition comprising administering to a subject in need a therapeutically effective amount of a molecule selected from (i) caspase-8 or a fragment thereof; (ii) a polynucleotide encoding caspase-8 or a fragment thereof; (iii) a vector comprising the polynucleotide of (ii); (iv) an activator of the level or activity of caspase-8; (v) an inhibitor of a natural inhibitor of casapase-8 activation; (vi) an inhibitor of the level or activity of a protein which is normally downregulated by caspase-8 activity in the skin; and (vii) and an activator of the level or activity of protein which is normally upregulated by caspase-8 in the skin.
An activator of caspase-8 level or activity includes, but is not limited to, FADD, caspase-6, caspase-3 or receptors of the TNF/NGF family.
An inhibitor of a natural inhibitor of casapase-8 activation may be an inhibitor of cFLIP short, cFLIP long, and caspase-8- and caspase-10-associated RING proteins, such as siRNA or shRNA specific to, cFLIP short, cFLIP long, or caspase-8- and caspase-10-associated RING proteins.
An agent that is an inhibitor of the level or activity of a protein which is normally downregulated by caspase-8 activity in the skin, may be an inhibitor of the level or activity of a protein encoded by a sequence selected from, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and a homologous human gene thereof. In one embodiment of the invention, the agent is an inhibitor of the level or activity of a protein encoded by the sequence set forth in SEQ ID NO: 2 or a homologous human gene thereof. In another embodiment of the invention, the agent is an inhibitor of the level or activity of a protein encoded by the sequence set forth in SEQ ID NO: 3 or a homologous human gene thereof. In a further embodiment of the invention the inhibitor is a siRNA or shRNA specific to a protein encoded by a sequence set forth in SEQ ID NO: 1, and preferably in SEQ ID NO: 2, SEQ ID NO: 3 or a homologous human gene thereof.
In certain embodiment, the disease is atopic dermatitis.
In other embodiment, the disease is psoriasis.
In a further embodiment of the invention the agent is used or administered topically.
In another aspect, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an inhibitor of the activity or level of expression of a protein encoded by the sequence of SEQ ID NO: 1, and SEQ ID NO: 2, SEQ ID NO: 3, and/or a homologous human gene thereof.
In one embodiment, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an inhibitor of the activity or level of expression of a protein encoded by the sequence of SEQ ID NO: 1, SEQ ID NO: 2 and/or a homologous human gene thereof.
In another embodiment, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an inhibitor of the activity or level of expression of a protein encoded by the sequence of SEQ ID NO: 1, SEQ ID NO: 3, and/or a homologous human gene thereof.
In a further embodiment, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an inhibitor of the activity or level of expression of a protein encoded by the sequence of SEQ ID NO: 2, and SEQ ID NO: 3, and/or a homologous human gene thereof.
In another further embodiment, the inhibitor is a siRNA or shRNA capable of silencing expression of a protein encoded by a sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or a homologous human gene thereof.
In another further embodiment, the inhibitor is a siRNA or shRNA specific to a protein encoded by a sequence set forth in SEQ ID NO: 2, SEQ ID NO: 3 or a homologous human gene thereof.
In another further embodiment, the pharmaceutical, composition is for the treatment of atopic dermatitis.
In another further embodiment, the pharmaceutical composition is for the treatment of psoriasis.
In another aspect, the invention provides a method for diagnosing in an individual a skin disease, disorder or condition associated with caspase-8 deficiency in the skin or the predisposition to develop said skin disease, disorder or condition, comprising, measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the expression level or activity of caspase-8 and/or detecting aberrations in nucleic acid encoding caspase-8 in a sample of skin from the tested individual, wherein detection of a decrease of caspase-8 activity or expression level in the sample of the tested individual as compared to the sample of said at least one healthy control individual, and/or detection of aberrations in nucleic acid encoding caspase-8 in the tested individual is indicative of said skin disease, disorder or condition, or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
In one embodiment, the method is for diagnosing in all individual a skin disease, disorder or condition associated with caspase-8 deficiency in epithelial keratinocytes or the predisposition to develop said skin disease, disorder or condition.
In a further embodiment, the method is for diagnosing atopic dermatitis.
In another further embodiment, the method is for diagnosing proriasis.
In an additional aspect, the invention provides a method for diagnosing in an individual an inflammatory skin disease, disorder or condition or a predisposition to develop said skin disease, disorder or condition, comprising measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the level of expression or activity of a protein encoded by a human gene homologous to a gene set forth in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, wherein detection of an increase of the expression level or activity of a protein encoded by a human gene homologous to the gene set forth in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 in the sample of the tested individual as compared to the sample of said at least one healthy control individual is indicative of said skin disease, disorder or condition or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
In another additional aspect, the invention provides a method for diagnosing in an individual an inflammatory skin disease, disorder or condition or a predisposition to develop said skin disease, disorder or condition, comprising measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the level of expression or activity of a protein encoded by a human gene homologous to a gene set forth SEQ ID NO: 2, wherein detection of an increase of the expression level or activity of a protein encoded by a human gene homologous to the gene set forth in SEQ ID NO: 2 in the sample of the tested individual as compared to the sample of said at least one healthy control individual is indicative of said skin disease, disorder or condition or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
In a further additional aspect, the invention provides a method for diagnosing in an individual an inflammatory skin disease, disorder or condition or a predisposition to develop said skin disease, disorder or condition, comprising measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the level of expression or activity of a protein encoded by a human gene homologous to a gene set forth SEQ ID NO: 3, wherein detection of an increase of the expression level or activity of a protein encoded by a human gene homologous to the gene set forth in SEQ ID NO: 3 in the sample of the tested individual as compared to the sample of said at least one healthy control individual is indicative of said skin disease, disorder or condition or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
In a still further additional aspect, the invention provides a method for diagnosing in an individual an inflammatory skin disease, disorder or condition or a predisposition to develop said skin disease, disorder or condition, comprising measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the expression level or activity of one, more than one, two, three, four, five, six, seven, eight, nine, or all of the following proteins selected from ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, or IL1b, and of a protein encoded by a human gene homologous to 9230117E20Rik (SEQ ID NO: 2), or a protein encoded by a human gene homologous to 2010002N04Rik (SEQ ID NO: 3), wherein detection of an increase of the expression level or activity of said one, more than one, two, three, four, five, six, seven, eight, nine, or all of the following proteins selected from ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, or IL1b, and of a protein encoded by a human gene homologous to 9230117E20Rik (SEQ ID NO: 2), or a protein encoded by a human gene homologous to 2010002N04Rik (SEQ ID NO: 3) in the sample of the tested individual as compared to the sample of said at least one healthy control individual is indicative of said skin disease, disorder or condition or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
In one embodiment of the invention, measuring the expression level or activity of the protein in the sample of skin is effected by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) analysis, immunoassay, in situ hybridization analysis and/or by measuring enzymatic activity.
In one embodiment of the invention, the sample of skin consists of epidermis.
In a further embodiment of the invention, the inflammatory skin disease is atopic dermatitis.
In another further embodiment of the invention, the inflammatory skin disease is psoriasis.
In another aspect, the invention provides a method for generating an animal model of an inflammatory skin disease, disorder or condition, comprising developing an animal arrested in keratinocyte caspase-8 expression level or activity. The method may employ knocking out caspase-8 in epithelial keratinocyte of the animal or induction of transgenic expression of caspase-8 mutant lacking enzymatic activity in the animal such as the caspase-8 BAC-C362S mutant. The animal model may be a mouse animal model.
In one embodiment, it is provided a method for generating an animal model for atopic dermatitis.
In another embodiment, it is provided a method for generating an animal model for psoriasis.
The invention relates to a method for identifying a target protein involved in the pathology or course of a skin disease, disorder or condition, such as an inflammatory disease, disorder or condition, whose level of expression or activity is normally regulated by caspase-8 activity in the skin comprising the steps of: comparing the profile of gene expression in a sample of skin comprising epithelial keratinocytes arrested in caspase-8 expression level or activity to the profile of gene expression in a sample of skin comprising epithelial keratinocytes having normal caspase-8 expression level or activity; assessing a gene whose expression is normally upregulated or downregulated by caspase-8 in the sample of skin comprising epithelial keratinocytes having normal caspase-8 expression level or activity, and whose expression is downregulated or upregulated in the sample comprising epithelial keratinocytes arrested in caspase-8 expression level or activity, respectively, wherein a gene whose expression is downregulated or upregulated in the sample comprising epithelial keratinocytes arrested in caspase-8 expression level or activity encodes a candidate target protein involved in the pathology or course of said skin disease, disorder or condition.
In one embodiment of the invention the disease is atopic dermatitis.
In another embodiment of the invention the disease is atopic psoriasis.
In a still another aspect, the invention provides a target protein involved in the pathology or course of an inflammatory skin disease, disorder or condition encoded by a human gene homologous to a gene set forth in SEQ ID NO: 2.
In a still another aspect, the invention provides a target protein involved in the pathology or course of an inflammatory skin disease, disorder or condition encoded by a human gene homologous to a gene set forth in SEQ ID NO: 3.
In certain aspects, the invention provides a method of screening of a candidate compound for treating or preventing a skin inflammatory disease, disorder or condition comprising, providing a culture of cells comprising keratinocytes arrested in caspase-8 expression level or activity, introducing a test compound in said cells, inducing differentiation of the cells by increasing the calcium concentration in the culture medium of the cells, measuring the expression level of a differentiation marker of the skin and/or p21ARF in the presence or absence of the test compound, wherein increase in the expression level of a differentiation marker of the skin and/or decrease of p21ARF in the presence of the test compound is indicative that the test compound is a candidate compound for treating or preventing said disease, disorder or condition.
In one embodiment of the invention the differentiation marker is keratin 1, filagrin, and/or loricrin.
In certain aspects, the invention also provides a method for testing the efficacy of a candidate compound for treating a skin inflammatory disease, disorder or condition, comprising administering to an animal model generated according to the invention the candidate test compound and assessing prevention or reduction of skin pathology in said animal model.
It has been found according to the present invention, that deficiency of caspase-8 in the skin is associated with the development of an inflammatory skin disease. We found that transgenic expression in mice of an enzymatically inactive caspase-8 (BAC-C362S), which apparently inhibits the activity of the endogenous caspase-8, or that specific deletion of capsase-8 in keratinocytes in mice, induces inflammatory skin hyperplasia. We also found that arrest of keratinocyte differentiation is involved in the pathology induced by deficiency of caspase-8 activity. Notably, the epidermis of mice having specific deletion of caspase-8 in keratinocytes (Casp-8fl/−K5-Cre mice) or of transgenic mice expressing enzymatically inactive caspase-8 (Casp-8−/+/BAC-C362S mice) displayed similar features to epidermis of atopic dermatitis (AD) patients such as a local elevation of eosinophiles at the damaged site and induction of TH2 response.
The findings according to the invention, that development of a skin inflammatory disease, disorder or condition, is caused by caspase-8 deficiency in the skin, paves the way to the development of new therapies to treat or prevent said disease disorder or condition.
Thus, the invention relates to the prevention or treatment of an inflammatory skin disease, disorder or condition, by modulating a protein that is normally regulated by caspase-8 in the skin or by increasing caspase-8 in the skin. Thus, in one aspect, the present invention relates to the use of an agent selected from, caspase-8 or a fragment thereof; a polynucleotide encoding caspase-8 or a fragment thereof; a vector comprising said polynucleotide; an activator of the level or activity of caspase-8; an inhibitor of a natural inhibitor of casapase-8 activation; an inhibitor of the level or activity of a protein which is normally downregulated by caspase-8 activity in the skin; and an activator of the level or activity of protein which is normally upregulated by caspase-8 in the skin, in the manufacture of a medicament for the treatment or prevention of an inflammatory skin disease, disorder or condition.
U.S. Pat. Nos. 6,399,327 and 6,586,571, of the present applicant, incorporated herein by reference, disclose inter alia the amino acid sequence of caspase-8 (or as previously designated, MACH) and the nucleotide sequence encoding caspase-8, assays of protease (or enzymatic) activity of caspase-8, and the binding of caspase-8 to the protein MORT-1 (or FADD).
A “fragment” according to the present invention may be an active fragment of caspase-8. The term fragment refers to any subset of the caspase-8 molecule, that is, a shorter peptide that retains the desired biological activity of caspase-8. Fragments may readily be prepared by removing amino acids from either end of caspase-8 and testing the resultant fragment for its enzymatic activity. Proteases may be used for removing one amino acid at a time from either the N-terminal or the C-terminal of a polypeptide are known, and thus determining fragments, which retain the desired biological activity, involves only routine experimentation and are described in U.S. Pat. Nos. 6,399,327 and 6,586,571, of the present applicant.
It should be understood that modified caspase-8 molecules having qualitatively the same biological activity as caspase-8 are encompassed herein by the invention. These modified caspase-8 include: (i) muteins, analogs in which one or more of the amino acid residues are deleted or replaced by different amino acid residues, and/or one or more amino acid residues are added, without changing considerably the activity of the resulting products as compared with the original protein, and obtained by known synthesis and/or site-directed mutagenesis techniques; (ii) functional derivatives, obtained by chemical substitution of functional groups in side chains of amino acid residues or at the N- and/or C-terminal groups, as long as they remain pharmaceutically acceptable, i.e., they do not destroy the activity of the protein. Such derivatives may, for example, include esters, amides and polyethylene glycol (PEG) side-chains; and (iii) salts, including both salts of carboxyl groups and acid addition salts of amino groups of the polypeptide.
The invention relates also to the use of a polynucleotide encoding caspase-8 or a fragment thereof, or of an expression vector comprising said polynucleotide in the manufacture of a medicament for the treatment or prevention of an inflammatory skin disease disorder or condition.
The term “nucleic acid molecule” or “polynucleotide” as used herein refers to a deoxyribonucleotide or ribonucleotide polymer in either single-stranded or double-stranded form, and, unless specifically indicated otherwise, encompasses polynucleotides containing known analogs of naturally occurring nucleotides that can function in a similar manner as naturally occurring nucleotides. It will be understood that when a nucleic acid molecule is represented by a DNA sequence, this also includes RNA molecules having the corresponding RNA sequence in which “U” (uridine) replaces “T” (thymidine).
The polynucleotides of the invention include also polynucleotides that comprise degenerate codons and/or which hybridize under highly stringent conditions to the complementary sequences of said polynucleotides.
The term “stringent conditions” refers to a temperature and ionic conditions used in a nucleic acid hybridization reaction (See Ausubel et al., Current Protocols in Molecular Biology, supra, Interscience, N.Y., §§6.3 and 6.4 (1987, 1992), and Sambrook et al. (Sambrook, J. C., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Stringent conditions are sequence dependent and are different under different environmental parameters. Generally, stringent conditions are selected to be about 5 to 10° C. or to 20° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature, under defined ionic strength and pH, at which 50% of the target sequence hybridizes to a perfectly matched probe. Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (for example, 10 to 50 nucleotides) and at least about 60° C. for long probes (for example, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Examples of stringent conditions include washing conditions 5° C. to 10° C. lower than the calculated Tm of the hybrid under study in, e.g., 2×SSC and 0.5% SDS for 5 minutes, 2×SSC and 0.1% SDS for 15 minutes; 0.1×SSC and 0.5% SDS at 37° C. for 30-60 minutes and then, a 0.1×SSC and 0.5% SDS at 68° C. for 30-60 minutes.
The polynucleotides of the invention include also polynucleotides that comprise degenerate codons. Because of the degeneracy of the genetic code, a large number of functionally identical polynucleotides encode any given polypeptide. For instance, the codons CGU, CGC, CGA, CGG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. It will also be recognized that each codon in a polynucleotide, except AUG, which is ordinarily the only codon for methionine, and UUG, which is ordinarily the only codon for tryptophan, can be modified to yield a functionally identical molecule by standard techniques.
Expression vectors are well known in the art and are described, for example in Current Protocols in Molecular Biology. Expression vectors can be a plasmid vector, viral vector, and the like. Generally, the vector contains a selectable marker independent of that encoded by a polynucleotide of the invention, and further can contain transcription regulatory element such as a promoter or polyadenylation signal sequence, or a translation regulatory element such as a ribosome binding site. A promoter sequence can provide tissue specific expression of a polynucleotide operatively linked thereto. In one embodiment the promoter is active in skin cells. In another embodiment of the invention, the promoter is active in epidermis cells.
The invention also provides the use of an activator of the level or activity of caspase-8 in a skin inflammatory disease, disorder or condition.
The term “activator of a protein” within the context of this invention refers to any agent, such as a protein, nucleotide and small molecule, capable of up-regulating said protein production and/or action. For example, an activator of caspase-8 may be a molecule that act upstream of caspase-8 in the skin.
Examples of activators of caspase-8 include, but are not limited to, FADD, caspases that can cleave caspase-8, that is—caspase-6 and caspase-3 and, indirectly, the various death receptors of the TNF/NGF family. Depending on the exact cellular set up, cFLIP long may also serve as caspase-8 activator.
A vector for inducing and/or enhancing the endogenous production of caspase-8 is also contemplated as an activator of caspase-8 according to the invention. The vector may comprise regulatory sequences capable of enhancing the expression of caspase-8. Such regulatory sequences may be, for example, promoters or enhancers. The regulatory sequence may then be introduced into the right locus of the genome by homologous recombination, thus operably linking the regulatory sequence with the gene, the expression of which is required to be induced or enhanced. The technology is usually referred to as “endogenous gene activation” (EGA), and it is described, e.g., in WO 91/09955 and is fully incorporated by reference herein.
The invention also provides the use of an inhibitor of a natural inhibitor of caspase-8 activation in a skin inflammatory disease, disorder or condition.
The following are examples of natural inhibitors of caspase-8 activation, whose level or activity may be inhibited according to the invention, which include but are not limited to, (i) cFLIP short (CASH beta) (ii) cFLIP long (CASH alpha). (iii) The caspases-8- and -10-associated RING proteins (CARPs, McDonald E R 3rd, El-Deiry W S, Proc Natl Acad Sci USA. 2004 Apr. 20; 101(16):6170-5).
The term “inhibitor” within the context of this invention refers to any agent such as a protein (e.g. a specific antibody), nucleotide (e.g. a specific antisense and small Interfering RNAs [siRNA]) and a specific inhibitory small molecule capable of down-regulating the production and/or action of a protein in such a way that said protein production and/or action is attenuated, reduced, or partially, substantially or completely prevented or blocked.
For example, a specific siRNA can be used for post-transcriptional silencing of specific mRNA targets (Dorsett and Tuschl 2004). Target specificity in RNAi is achieved through RNA-RNA sequence recognition and base pairing. The siRNA consists of double stranded RNA, typically of 19-21 base pair long, with two nucleotides overhanging at each 3′ end. For maximal stability, two 2′ deoxynucleotides are used as 3′ overhangs. Alternatively, 27-mer blunt-ended nucleotides may be used, as these have shown improved efficiency in gene silencing (Kim, Behlke et al. 2005). Transport of siRNA into cells may be enhanced by encapsulation into liposomes or by covalent coupling to highly lipophilic agents. Soutschek et al (2004).
Another example of an inhibitor of expression is a specific short hairpin RNA (shRNA). Designing and cloning strategies for constructing shRNA expression vectors are known in the art (McIntyre and Gregory et al BMC Biotechnology 2006, 6:1).
In one aspect, the invention relates to the use of an inhibitor of the level or activity of a protein, which is normally downregulated by caspase-8 activity in the skin, in the treatment or prevention of an inflammatory skin disease, disorder or condition.
A protein, which is normally downregulated by caspase-8 activity in the skin, can become upregulated when caspase-8 activity or level in the skin is arrested. The following are non limiting examples of proteins which are normally downregulated directly or indirectly by caspase-8 activity in the skin and that were found according to the present invention: ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue is called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, IL1b, and proteins of unknown function such as homologous human proteins to the proteins encoded by 9230117E20Rik (SEQ ID NO: 2), 2010002N04Rik (SEQ ID NO: 3).
In certain embodiments, the invention relates to the use of an inhibitor capable of inhibiting the level or activity of a protein encoded by SEQ ID NO: 1, preferably, SEQ ID NO: 2 and/or SEQ ID NO: 3 or by a homologous human gene. The inhibitor may be a siRNA or shRNA specific to a SEQ ID NO: 1, preferably, SEQ ID NO: 2, SEQ ID NO: 3 and/or a homologous human gene thereof.
The amino acid sequence of the protein encoded by the sequence set forth in SEQ ID NO: 1 is SEQ ID NO: 4, the amino acid sequence of the protein encoded by the sequence set in SEQ ID NO: 2 is SEQ ID NO: 5, and the amino acid sequence of the protein encoded by the sequence in SEQ ID NO: 3 is SEQ ID NO: 6.
In another aspect, the invention relates to the use of an activator of the level or activity of a protein which is normally activated or upregulated by caspase-8 activity in the skin, in the treatment or prevention of an inflammatory skin disease, disorder or condition. These proteins can be identified or screened by methods according to the invention to identify or screen of a target protein involved in the pathology or course of a skin inflammatory disease disorder or condition as described below.
The agent or molecule according to the invention may be used in a variety of ways and routes. For example, the agent or molecule can be used topically, into, to, or on the skin or can be adsorbed through epithelial or endothelial tissues.
We found according to the invention, that in spite that the inflammatory hyperplasia mediated by caspase-8 deficiency displayed enhanced cell division in the basal epithelial layer and withheld differentiation, the pathological state was not associated with deficient apoptosis. In fact, the incidence of dying cells in the Casp-8−/+/BAC-C362S and Casp-8fl/−K5-Cre epithelium was higher than in normal epithelium (
Only one caspase, caspase-14, of yet unknown function, is uniquely expressed in epithelial cells, and has reproducibly been shown to be cleaved during the cornification (Takahashi et al., 1998, Lippens et al., and Lippens et al., 2003). We have found according to the invention, that cleavage or activation of caspase-14 is not affected in the inflammatory hyperplasia mediated by caspase-8 deficiency.
It has been speculated in the art that the nonapoptotic functions of caspase-8 do not depend on its enzymatic activity, since overexpression of enzymatically inactive caspase-8 can trigger NF-κB activation, and in view of the evidence for signaling activities of cFLIP, an enzymatically inactive caspase-8 homologue that seems to participate in at least part of the caspase-8 nonapoptotic functions. However, the contribution of caspase-8 to T cell growth has recently been shown in the art to depend on its enzymatic function. In the latter case, evidence was presented for a role of the caspase-8 enzymatic function in activation of the p65/p50 NF-κB dimers. We have found according to the invention that the role of caspase-8 in epidermal differentiation does depend on its enzymatic proficiency.
Although the pathology of the caspase-8 deficient epidermis somewhat resembles that observed in the skin lacking p65 NF-κB (Zhang et al, 2004), the cellular events affected in these two cases seem to differ. For example, arrest of p65 NF-κB activation in epidermis results in excessive growth of the keratinocytes, which unlike the case of capsase-8 deficiency, is manifested by a marked thickening of the basal layer and seems not to affect keratinocyte differentiation. Moreover, while the skin pathology consequent from the arrest of NF-κB activation in the keratinocytes results from excessive increase in Jun phosphorylation, and fully depends on TNF function, the pathology resulting from caspase-8 deficiency seems not to involve any increase in Jun phosphorylation and, even though enhanced by TNF, it does not fully depend on it. Thus, it seems unlikely that the pathology resulting from caspase-8 deficiency reflects a role of caspase-8 in regulation of activation of the p65/p50 NF-κB dimers. In fact, we found according to the invention that there is no difference between the extents of nuclear translocation of these NF-κB proteins in the model mice of caspase-8 deficient epithelium compared to normal mice.
Our findings show that mice with a keratinocyte-specific deletion of the caspase-8 gene developed an inflammatory skin disorder that was, in part, perpetuated by TNF. However, we found according with the invention that the differentiation insufficiency that initiates the pathology reflects a cell-autonomous role of caspase-8, which is independent of TNF, yet depends on the caspase-8 enzymatic activity.
The results obtained according to the invention show that a skin disease, that may be optimally treated or prevented by administering an agent of the invention is a skin disease exhibiting one or more histological and/or immunological features resembling those found in the inflammatory disease that is mediated by caspase-8 deficiency in the skin and particularly in the epidermis, said skin disease may comprise one, more than one, two, three, four, five, six, seven, eight or all of the following features: (i) accumulation of leukocytes in the dermis, mainly mononuclear phagocytes and/or eosinophils; (ii) lack of increase of either T or B lymphocytes; (iii) expression of Keratin 6 in the epidermis specifically at the site of the epithelial lesion; (iv) significant suprabasal expression of keratin 14 (K14); (v) K6 and K14 expression in all viable layers; (vi) reduced or absent expression of the suprabasal keratin 1 (K1); (vii) reduced or absent expression of one or more skin differentiation markers selected from keratin 1, loricrin and filaggrin; (viii) increased expression of one, more than one, two, three, four, five, six, seven, eight, nine, or all of the following proteins: ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue is called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, IL1b; (ix) increased expression of a human protein homologous to the one encoded by SEQ ID NO:2 or by SEQ ID NO: 3; (x) increase of TH2 response, as supported by elevated expression of IL-4, IL-5 (evidenced by the increase in eosinophiles that is mediated by this cytokine, Kupper et al., 2004) and IL-19; (xi) activation of Stat-1 and Stat-3 in the epidermis; (xii) upregulation of S100A8 in the dermis; (xiii) and no impairment of caspase-14 processing. For example, an agent according to the invention can be used to treat a disease like AD since AD has features resembling that found in the epidermis of the Casp-8fl/−K5-Cre mice and in the Casp-8−/+/BAC-C362S mice such as accumulation eosinophils and increase of TH2 response.
Thus, a disease that may be optimally treated or prevented by administering an agent selected from, caspase-8 or a fragment thereof; a polynucleotide encoding caspase-8 or a fragment thereof; a vector comprising said polynucleotide; an activator of the level or activity of caspase-8; an inhibitor of a natural inhibitor of casapase-8 activation; an inhibitor of the level or activity of a protein which is normally downregulated by caspase-8 activity in the skin; and an activator of the level or activity of protein which is normally upregulated by caspase-8 in the skin; includes, but is not limited to, psoriasis and atopic dermatitis.
Further aspects of the invention relate to methods for identifying target proteins involved in the pathology or course of an inflammatory skin disease, disorder or condition. According to the present invention, we have developed a method for identifying a target protein involved in the pathology or course of a skin disease, disorder or condition whose level of expression or activity is normally regulated by caspase-8 activity in the skin comprising the steps of: comparing the profile of gene expression in a sample of skin comprising epithelial keratinocytes arrested in caspase-8 expression level or activity to the profile of gene expression in a sample of skin comprising epithelial keratinocytes having normal caspase-8 expression level or activity; assessing a gene whose expression is normally upregulated or downregulated by caspase-8 in the sample of skin comprising epithelial keratinocytes having normal caspase-8 expression level or activity, and whose expression is downregulated or upregulated in the sample comprising epithelial keratinocytes arrested in caspase-8 expression level or activity, respectively, wherein a gene whose expression is downregulated or upregulated in the sample comprising epithelial keratinocytes arrested in caspase-8 expression level or activity encodes a candidate target protein involved in the pathology or course of said skin disease, disorder or condition.
In certain embodiments, the method of the invention employs a sample of skin that is from a human or mouse origin.
The profile of expression of a gene can be measured by tools that are well known in the art such as microarray analysis, Western blotting analysis, in situ hybridization, and RT-PCR, as shown in the Examples below. In one embodiment of the invention, the profile of gene expression is monitored by gene arrays, for example as carried out in the non-limiting examples.
By using the method of the invention we identified the following genes (and encoded proteins) whose expression is upregulated in samples of skin comprising epithelial keratinocytes arrested in caspase-8 activation; ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue is called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, IL1b. These genes are involved in inflammatory processes. Thus, in one embodiment of the invention, the method allows the identification of a target gene (or the encoded protein) involved in the pathogenesis or course of a skin inflammatory disease, disorder or condition such as psoriasis and atopic dermatitis. Proteins encoded by SEQ ID NO: 1, and proteins of unknown function encoded by 9230117E20Rik (SEQ ID NO: 2) and 2010002N04Rik (SEQ ID NO: 3) have been positively selected herein by the method of the invention. Since these proteins or homologous human proteins are regulated by caspase-8 in the skin, they play a role in development and/or homeostasis of the skin and therefore are candidates to be target proteins involved in the pathology or course of an inflammatory skin disease, disorder or condition.
Thus, an inhibitor of expression of a gene corresponding to SEQ ID NO: 1, SEQ ID NO: 2, and/or SEQ ID NO: 3, or a homologous human gene thereof and/or an inhibitor of a protein encoded by said gene may be beneficial for the treatment or prevention of a skin inflammatory disease, disorder or condition such as atopic dermatitis or psoriasis.
Thus, in one aspect, the present invention relates to the use of an inhibitor of a gene corresponding to SEQ ID NO: 1, SEQ ID NO: 2, and/or SEQ ID NO: 3, or a homologous human gene thereof and/or to an inhibitor of a protein encoded by each of said genes in the manufacture of a medicament for the treatment or prevention of an inflammatory skin disease disorder or condition.
In another aspect, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an inhibitor of a gene comprising the sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, or of a homologous human gene thereof and/or an inhibitor of a protein encoded by said gene, for example, for the treatment or prevention of a skin inflammatory disease, disorder or condition such as atopic dermatitis or psoriasis.
In certain embodiment, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an inhibitor of a gene comprising the sequence of SEQ ID NO: 2, or a homologous human gene thereof and/or an inhibitor of a protein encoded by said gene.
In other embodiment, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an inhibitor of a gene comprising the sequence of SEQ ID NO: 3, or a homologous human gene thereof and/or an inhibitor of a protein encoded by said gene.
In a further embodiment of the invention, the inhibitor in the pharmaceutical composition is a siRNA or shRNA specific to a SEQ ID NO: 1, preferably, SEQ ID NO: 2, SEQ ID NO: 3 or of a homologous human gene thereof.
Publications relating to the function of caspase-3 (Okuyama et al., 2004), a major effector caspase, revealed that apart from its participation in death induction by a variety of agents, caspase-3 is involved, at a particular phase of during embryonic development known as midgestation, in the induction of differentiation of the skin epidermis in mouse. In fact, the enzymatic activity of caspase-3 is essential for maintaining the keratinocyte commitment to terminal differentiation during embryonic development of the skin.
We found according to the invention that although the Casp8BAC-C362S transgenic is expressed in the mouse, just as the endogenous caspase-8, at early stages of embryogenesis, and the keratin-5-induced expression of Cre in Casp-8fl/−K5-Cre mice occurs in embryogenesis stages, the skin pathology in these mice was not apparent earlier than three days after birth. At the time of birth, the histological features of the skin were indistinguishable from that of the wild-type mice, suggesting that, unlike caspase-3, caspase-8 is dispensable for embryonic development of the skin epithelium.
It has been shown according to the invention that caspase-8 plays a similar role to caspase-3 in the postnatal epidermal morphogenesis since targeted elimination of caspase-8 expression in the skin resulted in increased proliferation and decreased expression of the late differentiation markers in the postnatal, but not in the embryonic keratinocytes.
The contribution of caspase-3 to the regulation of keratinocyte differentiation at a distinct phase of midgestation has been correlated to a Notch1-induced increase in expression of caspase-3 in this phase, and was suggested to reflect a role of caspase-3-induced processing of PKC-d in activation of the latter kinase. In contrast, we found that caspase-8 deficiency compromises the downregulation of p21, which precedes the induction of the differentiation proteins in the keratinocytes.
Normal homeostasis of the skin and pathological aberrations of the skin are affected by a constant cross-talk between the epidermis and the dermis, as well as among the cells of each of these two layers, through the release of various soluble mediators. We found according to the present invention that the epidermal pathology observed in the absence of caspase-8 is associated with accumulation of inflammatory cells, mainly leukocytes, in the dermis and is strongly affected by the function of TNF, produced by these inflammatory cells, by the keratinocytes themselves, or perhaps by both. Through assessment of the differentiation capacity of the keratinocytes in culture we found that the differentiation program of these cells shifts to a caspase-8 dependent state at about one day after birth, clearly before the accumulation of leukocytes in the dermis, and that this shift occurs independently of TNF. Several differentiation-related keratinocyte proteins were found to be affected by caspase-8 deficiency at about one day after birth. However, pathological manifestations in vivo, appear only later, at a rate that does depend on TNF, and perhaps on some other leukocytes-produced mediators. Thus, our results show that TNF function and the accumulation of leukocytes are not central to the change that occurs in the epithelium but just serve auxiliary roles in it.
Another aspect of the invention relates to methods for screening a candidate compound for treating a skin inflammatory disease, disorder or condition. The above findings with cultures of isolated keratinocytes deficient in caspase-8 showing that differentiation-related keratinocyte proteins are affected by caspase-8, paved the way to the development of a method for screening of a candidate compound for treating a skin inflammatory disease, disorder or condition. The method according to the invention comprises, providing a culture of cells comprising keratinocytes arrested in caspase-8 expression level or activity, introducing a test compound in said cells, inducing differentiation of the cells by increasing the calcium concentration in the culture medium of the cells, measuring in the cells the expression level of a differentiation marker of the skin and/or p21ARF in the presence or absence of the test compound, wherein increase in the expression level of a differentiation marker of the skin and/or decrease of p21ARF in the presence of the test compound is indicative that the test compound is a candidate compound for treating or preventing said disease, disorder or condition. Culture of cells comprising keratinocytes arrested in caspase-8 expression level or activity can be isolated from mice expressing transgenic inactive mutant caspase-8 or mice exhibiting conditional caspase-8 knockout in the skin, for example, as shown in the examples. A candidate compound may be screened from libraries of chemicals or natural agents. Introducing the test compound in the cells may be carried out for example by adding the test compound in the culture medium of the cells. Measuring the expression level of the proteins in the cells can be done by RT-PCR analysis, or by immunoassay analysis as carried out in the examples below employing protein specific antibody. In one embodiment of the invention, the method measures the levels of keratin 1, filagrin and/or loricrin, for example by immunoassay analysis.
According to the present invention, we have generated an animal model of an inflammatory skin disease, disorder or condition by developing an animal arrested in keratinocyte caspase-8 expression level or activity. The arrest of caspase-8 activity or level can be achieved as shown in the non limiting examples by knocking out caspase-8 in epithelial keratinocyte of the animal or by developing animals having endogenous caspase-8 but expressing also transgenic caspase-8 lacking enzymatic activity such as BAC-C362S in which the Cys at residue 362 has been replaced for Ser. In one embodiment of the invention the animal is mouse.
According to the invention, this animal model can be used to test the efficacy of a candidate compound for treating a skin inflammatory disease, disorder or condition such as atopic dermatitis or psoriasis. Thus in one aspect, the invention relates to a method to test the efficacy of a candidate compound for treating a skin inflammatory disease, disorder or condition comprising administering to an animal model generated according the invention a candidate test compound and assessing prevention or reduction of skin pathology in said animal model.
The results obtained by RT-PCR analysis confirmed that genes ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue is called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, IL1b, the human homologous gene of 9230117E20Rik (SEQ ID NO: 2), the human homologous gene of 2010002N04Rik (SEQ ID NO: 3) are unpregulated compared to the levels of expression of said genes in a sample of skin from a normal subject and that the same pattern of upregulation can be detected before the pathology develops in the skin (Example 6).
Thus, another aspect of the invention relates to methods for diagnosing an inflammatory skin disease, disorder or condition or a predisposition to develop said disease disorder or condition in an individual. In view of the findings of the present invention, the levels of caspase-8 activity or expression and/or expression of genes that are normally regulated by caspase-8 in the skin can be examined in a sample of skin or epidermis of an individual in order to find out whether the individual suffers or is likely to suffer of an inflammatory skin disease, disorder or condition. For example, if in a skin sample of a tested individual the levels of caspase-8 activity or expression are downregulated and/or the levels of expression or activity of one, more than one, two, three, four, five, six, seven, eight, nine, or all of the following genes (or encoded proteins) including, but not limited to, ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue is called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, IL1b and at least one gene of unknown function such as the human homologous genes of 9230117E20Rik (SEQ ID NO: 2) and 2010002N04Rik (SEQ ID NO: 3) are unpregulated, for example, by at least 15%, or up to 17%, 25%, 33%, 50%, 67%, and/or 100% compared to the levels of expression of said genes in a sample of skin of a healthy individual, one can assume that the tested individual has an inflammatory skin disease, disorder or condition or is likely to have or develop said skin disease, disorder or condition.
Thus in another aspect, the invention relates to a method for diagnosing in a tested individual a skin disease, disorder or condition associated with caspase-8 deficiency in epithelial keratinocytes or a predisposition or likelihood to develop said skin disease, disorder or condition, comprising measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the caspase-8 level or activity, and/or expression of genes that are normally regulated by caspase-8 in the skin and are unregulated in the skin disease, disorder or condition, and/or detecting aberrations in nucleic acid encoding caspase-8, wherein a decrease of the levels of caspase-8 activity or level, and/or presence of aberrations in nucleic acid encoding caspase-8, and/or unregulation of expression of genes that are normally regulated by caspase-8 in the skin in the tested individual compared to level, activity or expression in the skin of the said at least one healthy control individual is indicative of said skin disease, disorder or condition or of a likelihood or predisposition to develop said skin disease, disorder or condition in the tested individual.
Detecting nucleic acid aberration of caspase-8 in a sample of a tested individual can be carried out by methods well known in the art such as isolating RNA from a sample of skin of the tested individual, for example, as described in the examples below and sequencing caspase-8 of PCR amplified cDNA.
Characteristic activity of caspase-8 is its proteolytic activity at specific substrate sites. Thus, activity of caspase-8 in a sample can be determined by means of routine experimentation comprising subjecting such sample e.g. to a substrate as described in example 3 of U.S. Pat. No. 6,399,327.
Measuring the expression level of caspase-8 in the skin can be carried out by methods well known in the art such as by subjecting the sample to immunoassay employing caspase-8 specific antibody or by extracting RNA from the sample and employing RT-PCR using caspase-8 specific primers. Typically, RT PCR analysis include RT-PCR of a house keeping gene such as beta actin, as shown in the examples below, as control for sample load.
Thus, the invention provides a method for diagnosing in an individual a skin disease, disorder or condition associated with caspase-8 deficiency in the skin or the predisposition to develop said skin disease, disorder or condition, comprising, measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the expression level or activity of caspase-8 and/or detecting aberrations in nucleic acid encoding caspase-8 in a sample of skin from the tested individual, wherein detection of a decrease of caspase-8 activity or expression level in the sample of the tested individual as compared to the sample of said at least one healthy control individual, and/or detection of aberrations in nucleic acid encoding caspase-8 in the tested individual is indicative of said skin disease, disorder or condition, or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
The invention also provides a method for diagnosing in an individual an inflammatory skin disease, disorder or condition or a predisposition to develop said skin disease, disorder or condition, comprising measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the expression level or activity of a protein encoded by a human gene homologous to a gene set forth in SEQ ID NO: 1, SEQ ID NO: 2, and/or SEQ ID NO: 3, wherein detection of an increase of the expression level or activity of a protein encoded by a human gene homologous to the gene set forth in SEQ ID NO: 1, SEQ ID NO: 2, and/or SEQ ID NO: 3 in the sample of the tested individual as compared to the sample of said at least one healthy control individual is indicative of said skin disease, disorder or condition or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
In one embodiment the method comprises measuring the expression level of a protein encoded by a human gene homologous to a gene set forth in SEQ ID NO: 2. In another embodiment the method comprises measuring the expression level of a protein encoded by a human gene homologous to a gene set forth in SEQ ID NO: 3.
The expression level of a protein can be measured as exemplified below by methods well known in the art such as immunoassay and RT PCR.
In a further embodiment, the method is for diagnosing atopic dermatitis or for diagnosing predisposition to develop the disease.
The invention also provides a method for diagnosing in an individual an inflammatory skin disease, disorder or condition or a predisposition to develop said skin disease, disorder or condition, comprising measuring in a sample of skin of the tested individual and in a sample of skin of at least one healthy control individual the expression level or activity of one, more than one, two, three, four, five, six, seven, eight, nine, or all of the following proteins selected from ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, or IL1b, and of a protein encoded by a human gene homologous to 9230117E20Rik (SEQ ID NO: 2), or a protein encoded by a human gene homologous to 2010002N04Rik (SEQ ID NO: 3), wherein detection of an increase of the expression level or activity of said one, more than one, two, three, four, five, six, seven, eight, nine, or all of the following proteins selected from ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, or IL1b, and of a protein encoded by a human gene homologous to 9230117E20Rik (SEQ ID NO: 2), or a protein encoded by a human gene homologous to 2010002N04Rik (SEQ ID NO: 3) in the sample of the tested individual as compared to the sample of said at least one healthy control individual is indicative of said skin disease, disorder or condition or of a predisposition to develop said skin disease, disorder or condition in the tested individual.
In certain embodiments, the methods of the invention employ the sample of at least one a healthy control individual, in other embodiment of the invention a sample of a single healthy control individual, in further embodiments of the invention individual samples of more than one, two or three healthy control individuals or a pool of samples of two three or more healthy control individuals.
As used herein, a “gene” refers to a polynucleotide or portion of a polynucleotide comprising a sequence that encodes a protein. It is well understood in the art that a gene may also comprise non-coding sequences, such as 5′ and 3′ flanking sequences (such as promoters, enhancers, repressors, and other regulatory sequences) as well as introns.
The term “homologous” or “homologue” or “ortholog” is known and well understood in the art and refers to related sequences that share a common ancestor and is determined based on degree of sequence identity. These terms describe the relationship between a gene found in one species and the corresponding or equivalent gene in another species. For purposes of this invention homologous sequences are compared. “Homologous sequences” or “homologues” or “orthologs” are thought, believed, or known to be functionally related. A functional relationship may be indicated in any one of a number of ways, including, but not limited to, (a) degree of sequence identity (b) same or similar biological function. Preferably, both (a) and (b) are indicated. The degree of sequence identity may vary, but is preferably at least 50% (when using standard sequence alignment programs known in the art), more preferably at least 60%, more preferably at least about 75%, more preferably at least about 85%. Homology can be determined using software programs readily available in the art, such as those discussed in Current Protocols in Molecular Biology (F. M. Ausubel et al., eds., 1987) Supplement 30, section 7.718, Table 7.71. Preferred alignment programs are MacVector (Oxford Molecular Ltd, Oxford, U.K.) and ALIGN Plus (Scientific and Educational Software, Pennsylvania). Another preferred alignment program is Sequencher (Gene Codes, Ann Arbor, Mich.), using default parameters.
The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. These terms also include proteins that are post-translationally modified through reactions that include glycosylation, acetylation and phosphorylation.
The invention provides also, a method of treatment of a skin inflammatory disease, disorder or condition comprising administering to a subject in need a therapeutically effective amount of a molecule or an agent selected from: caspase-8 or a fragment thereof; a polynucleotide encoding caspase-8 or a fragment thereof; a vector comprising said polynucleotide; an activator of the level or activity of caspase-8; an inhibitor of a natural inhibitor of casapase-8 activation; an inhibitor of the level or activity of a protein which is normally downregulated by caspase-8 activity in the skin; and an activator of the level or activity of protein which is normally upregulated by caspase-8 in the skin.
The agent or molecule according to the invention can be administered to an individual in a variety of ways. In one embodiment, the agent or molecule is administered topically, into, to, or on the skin. Any other therapeutically efficacious route of administration can be used, for example absorption through epithelial or endothelial tissues or by gene therapy wherein a DNA molecule or polynucleotide encoding the agent is administered to the patient (e.g. via a vector), which causes the active agent to be expressed and secreted in vivo. In addition active ingredients according to the invention can be administered together with other components of biologically active agents such as pharmaceutically acceptable surfactants, excipients, carriers, diluents and vehicles.
The definition of “pharmaceutically acceptable” is meant to encompass any carrier, which does not interfere with effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which it is administered. For example, for parenteral administration, the active protein(s) may be formulated in a unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution.
The active ingredients of the pharmaceutical composition according to the invention can be administered to an individual in a variety of ways or routes. In one embodiment, the active ingredients are administered topically, into, to or on the skin. Any other therapeutically efficacious route of administration can be used. Active ingredients may be absorbed through epithelial or endothelial tissues. The active ingredient may be administered by gene therapy wherein a DNA molecule encoding the active agent is administered to the patient (e.g. via an expression vector), which causes the active agent to be expressed and secreted in vivo. In addition active ingredients according to the invention can be administered together with other components of biologically active agents such as pharmaceutically acceptable surfactants, excipients, carriers, diluents and vehicles.
Other routes of administration include intraliver, intradermal, transdermal (e.g. in slow release formulations), intramuscular, intraperitoneal, intravenous, subcutaneous, oral, epidural, topical, and intranasal routes. In addition the substance can be administered together with other components of biologically active agents such as pharmaceutically acceptable surfactants, excipients, carriers, diluents and vehicles.
The active ingredients can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable vehicle (e.g. water, saline, dextrose solution) and additives that maintain isotonicity (e.g. mannitol) or chemical stability (e.g. preservatives and buffers). The formulation is sterilized by commonly used techniques.
A “therapeutically effective amount” is such that when administered, the active ingredient results in prevention of the pathology, amelioration or beneficial improvement in the course of the disease. The dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties of active ingredients, the route of administration, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired. Adjustment and manipulation of established dosage ranges are well within the ability of those skilled in the art, as well as in vitro and in vivo methods of determining prevention of the pathology, amelioration or beneficial improvement in the course of the disease in an individual.
Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations and conditions without departing from the spirit and scope of the invention and without undue experimentation.
While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.
All references cited herein, including journal articles or abstracts, published or unpublished U.S. or foreign patent application, issued U.S. or foreign patents or any other references, are entirely incorporated by reference herein, including all data, tables, figures and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.
Reference to known method steps, conventional methods steps, known methods or conventional methods is not any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.
The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various application such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning an range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.
(i) Modification of a Bacterial Artificial Chromosome (BAC) Comprising Caspase-8.
A BAC clone from the RPCI-24 mouse (C57BL/6) BAC library, encompassing caspase-8, (RP24-238B22) was obtained from CHORI (BACPAC Resources). DH10B bacteria harboring the BAC clone were grown in LB medium containing 12.5 mg/ml of chloramphenicol. The presence of caspase-8 in the bacterial colonies was verified by PCR using oligonucleotides Exon8F-8R, Exon1F-1R, 5′UTRF-R [the oligonucleotides used are listed in section (i) below]. Modification of the BAC clone was performed essentially as described (Gong et al., 2002 and Sparwasser et al, 2004), using the pDelsac shuttle vector both for deleting the SacB gene from the RP24-238B22 clone and for modification of the caspase-8 gene. The following four modifications were introduced (see schematic
a. To monitor the expression of the transgenic in vivo, we placed an IRES sequence and the GFP cDNA, flanked by two sequences for the FRT recombination site, downstream of the stop codon of caspase-8. To introduce this sequence into the shuttle vector, the homology arms upstream and downstream of the stop codon (‘Box A’ and ‘Box B’, see diagrammatic presentation of the targeting cassettes in
b. To further assist monitoring the expression of the transgenic, we fused the T7 tag to the C-terminus of caspase-8 by introducing the T7 coding sequence to the EcoRI site in pBC FRT-IRES/GFP-FRT containing BoxA (derived from AF-AR2 PCR product) and BoxB of ‘a’ above.
c. To ease genotyping the transgenic mice, we exchanged a 20 nucleotide sequence within the first caspase-8 intron with a unique sequence (with equal nucleotide proportions). BoxC and BoxD were amplified using primer CF-CR and DF-DR. These two PCR products were used as a template in second PCR together with primer CF and DR that resulted in the fusion of two PCR fragments.
The findings presented in this study concern mice that express the BAC with all the above three modifications. Identical findings were reached with mice expressing BAC to which only the first modification (IRES/GFP) was introduced.
d. A catalytically inactive caspase-8 transgenic was generated by replacing the active-site cysteine at position 362 with serine (C362S), BoxI and BoxJ that border this sequence were amplified and fused by PCR using primers Box1S-IR and JF-Box2AS
All the above modification-cassettes were cloned into AscI-NotI sites of the pDelsac shuttle vector.
Following electroporation of the shuttle constructs to BAC-containing bacteria, and selection with chloramphenicol and ampicillin, colonies that had integrated the shuttle vector were identified by direct PCR or restriction enzyme analysis using the following primer pairs: TB3F-TB3R for AB or ATBCD, MutCF-1370R for CD, IF2-IR1 and HindIII for IJ).
Two or three positive colonies of each kind were then cultured in 5% sucrose to select for resolved BACs, followed by further selection by picking ampicilin-sensitive colonies. Positive colonies were validated by PCR (TB3F-TB3R, TB4F-TB4R for AB or ATBCD, 1130E-1370R, MutCF-1370R for CD, IF2-JR1 and HindIII for IJ) and restriction enzyme analysis as described above.
(ii) Isolation of BAC DNA for Microinjection.
BAC DNA was isolated by double acetate precipitation and cesium chloride gradient ultracentrifugation. After wash with ethanol, the BAC DNA was dissolved in TE buffer, lanearized by PI-SceI endonuclease (NEB) and drop-dialyzed for 6 hrs against microinjection buffer (10 mM Tris, pH7.5, 0.1 mM EDTA, pH8.0 and 100 mM NaCl) by floating on 0.025 μm Millipore membrane filter disc. The quality and quantity of BAC DNA was assessed by pulse-field gel electrophoresis (PFEG; 5 V/cm, 120 angle, lanear ramping time of 5-120 s for 24-30 hrs) in 1% agarose using CHEF-DR III PFEG system (Bio-Rad, check). The DNA was diluted to 2 ng/ul in injection buffer (10 mM Tris, pH7.5, 0.1 mM EDTA, pH8.0 and 100 mM NaCl) and mixed with equal volume of 2× polyamine (60 mM spermine and 140 mM spermidine in injection buffer) for the injection.
(iii) Generation and Analysis of BAG-Transgenic Mouse.
The DNA was injected at concentration of 1 ng/μl into the pronucleus of fertilized oocytes derived from CBF1 or C57BL/6 mice. Transgenic mice were identified both by PCR analysis (using primers Mut CF and IN1-1730R) of genomic DNA prepared from tail biopsies and by FACS analysis for GFP expression in the peripheral-blood leukocytes.
The catalytically inactive caspase-8 transgenic was distinguished from the active one by using primers IF2-JR1 for PCR followed by digestion with HindIII.
For Western blot analysis of various tissue extract from BAC tg mouse, tissue lysates from wild type and BAC transgenic mice were prepared by homogenization in lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris pH 7.4) following by boiling for 5 min. Protein concentration was determined with the BCA protein assay kit (Pierce). Aliquots of 25 μg protein were then analyzed by SDS-PAGE followed by immunoblotting with anti-mouse caspase-8 (3B10, kindly provided by Dr. A Strasser), anti-GFP and anti-human b-actin monoclonal antibodies (Sigma).
(iv). Development of K5 Cre casp8fl/+ and K5 Cre casp8fl/− Mice.
Mice in which one of the caspase-8 alleles was knocked out (casp-8+/−, Varfolomeev et al., 1998) were mated with a transgenic mouse lane that expressed Cre under control of the basal epithelia specific Keratin-5 promoter (K5 Cre Casp-8+, Ramirez et al., 1994). These K5 Cre Casp-8+ mice were then mated with mice carrying homozygous conditional caspase-8 allele (Casp-8flfl, Kang et al., 2004) to yield K5 Cre casp8fl/+ and K5 Cre casp8fl/− mice.
(v). Histology and Immunostaining.
Skin and other organs were fixed in 10% phosphate-buffered formalin pH 7.4, embedded in paraffin, cut into 4-μm sections, and stained with hematoxylin and eosin. Adjacent sections were used for immunostaining with the indicated antibodies. Cy-3 coupled secondary antibodies (Jackson Immunoresearch Labs) were used. Sections were further counterstained with Hoechst 33342 (Sigma) to visualize nuclei.
TUNEL staining kit (Roche Diagnostics) was used for detection of apoptotic cells.
Rabbit anti-cytokeratin 1, 6, 14, involucrin, filaggrin and loricrin antibodies were purchased from Covance. Mouse anti-p21 was purchased from Pharmingen. Rat anti-F4/80 was purchased from Serotec. Rat anti-Ki67 was purchased from DAKO.
(vi) Preparation of a Keratinocyte Culture.
Primary keratinocytes were isolated and cultured from newborn to four-days-old mice. Epidermis was separated from dermis with 3.3% tyrpsin (Gibco) overnight at 4° C. Keratinocytes were dissociated by shaking for 15 min in MEM medium and plated onto dishes with MEM medium supplemented with 10% chelex-treated fetal calf serum, antibiotics, KCl (400 μg) and 3% sodium bicarbonate.
To explore structure-function relationship in caspase-8 for the various effects that this enzyme exerts in vivo, we employed bacterial artificial chromosome (BAC) mediated transgenics (for details see Materials and Methods) to generate mice that apart from their endogenous caspase-8 alleles express an additional copy of the caspase-8 gene, or various mutants thereof (
We found that expression of enzymatically deficient caspase-8, Casp-8BAC-C362S, interferes with the function of co-expressed proficient enzyme, and induces the development of a skin inflammatory disease, suggesting that the caspase-8 enzymatic function plays a role in the development or homeostasis of the skin after birth.
In order to validate that the skin epidermal pathology observed in the mice expressing the Casp8BAC-C362S trangene reflects a functional role of caspase-8 in the epidermal cells themselves, we employed mice with a conditional caspase-8 allele to delete caspase-8 specifically in these cells (for details see Materials and Methods). Crossing mice in which part of one of the caspase-8 alleles was flanked by loxP sites and the other allele was deleted (Casp-8fl/−) with a transgenic mouse lane that expresses Cre under control of the kertatinocyte-specific Keratin-5 promoter resulted in effective and exclusive deletion of the caspase-8 gene in the epidermis as shown by PCR and Western blot analysis (
For Western blot analysis, skin was removed from P0 Casp-8fl/−K5-Cre mice and incubated for 2-3 seconds at 65° C. to separate epidermis and dermis. Both the epidermis and dermis samples were homogenized in RIPA buffer (50 mM Tris-HCl, pH 8.0, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM sodium chloride, 1 mM EDTA, 1 mM PMSF, 1 mM sodium orthovanadate, complete protease inhibitor cocktail) and left on ice for 30 min. Then cell homogenates were spun at 13000×g for 15 min and supernatants were removed. 40 μg of protein extracts were resolved in 10% SDS-polyacryamide gel and blotted onto nitrocellulose membranes. The membrane was incubated with anti-mouse caspase-8 (3B10, 1:2000 dilution, Alexis) or anti-beta Actin (1:10000 dilution, Sigma) and detected with anti-Rat-HRP (Sigma) or anti-Mouse-HRP in a standard ECL reaction (Pierce) according to the manufacture's instruction. The results of the Western blot analysis summarized in
The mice (Casp-8fl/−K5-Cre) appeared normal at birth. However, only 3 days later they started developing skin pathology similar to that of the Casp-8−/+/BAC-C362S mice (
In histological analysis (for details see Material and Methods), the epidermis of the Casp-8fl/−K5-Cre mice were found to display, just as in the Casp-8−/+/BAC-C362S mice, as well as features of inflammation such as accumulation of leukocytes in the dermis and expression of Keratin 6 in the epidermis (a marker for inflammatory and hyperproliferative condition) specifically at the site of the epithelial lesion. Furthermore, we found significant suprabasal expression of keratin 14 (K14) in the mutant skin, which is normally confined to the basal epidermal layer (
Arrest of activation of the p65 NF-kB protein in the skin keratinocytes, by knockout of either p65 itself or of IKK2, the kinase mediating p65 NF-kB activation, also results in inflammatory skin disorder (Hu et al. 1999, Pasparakis et al. 2002). In that case, the disorder was shown to be triggered by chronic autocrine stimulation of the keratinocytes by TNF and a resulting enhancement of Jun phosphorylation, which, in the absence of a restraining effect of co-activated p65 occurs to an excessive extent. To explore the relationship between this skin inflammatory process and that which occurs as a result of caspase-8 deficiency in the keratinocytes, we assessed the contribution of TNF to the latter. Deletion of either the TNF gene or the TNF receptor 1 (TNFR1) gene in the Casp-8fl/−K5-Cre mice by crossing them with the respective knockout mice resulted in a marked delay of initiation of the skin pathology (
In further distinction from the effect of p65 inhibition, no increase in Jun phosphorylation could be observed in the epidermis of the Casp-8fl/−K5-Cre mice (
Attempting to find out what role does caspase-8 serve in the skin keratinocytes, we first examined whether its deficiency affects cell death, a process with which caspase-8 is commonly associated. Tunnel tests revealed no decrease but rather significant increase of cell death in the caspase-8 deficient epidermis (
While the size of the epidermal basal layer remained unchanged, the pattern of expression of proteins that characterize distinct steps in differentiation of the keratinocytes was extensively altered in the caspase-8 deficient skin (
To find out if the aberrations of the cell differentiation pattern found in the caspase-8 deficient skin (
p21ARF, a nuclear protein participating in cell growth and differentiation control was shown to decrease dramatically in differentiating keratinocytes (Dotto 2000 and Di Cunto et al. 1998). This change appears to have a causative role in the gene-expression changes associated with the differentiation. By determining the amounts of p21ARF in the cultured keratinocytes we found that its decrease following induction of differentiation by calcium up-shift is significantly delayed in the caspase-8 deficient cell, indicating further that this deficiency interferes with some aspects of the differentiation process (
Thus, while cultured in vitro, caspase-8 knockout keratinocytes grow normally and withdraw from the cell cycle following application of elevated calcium. However, the molecular events normally associated with late differentiation steps fail to occur in the knockout culture. Most notably, expression of loricrin and filaggrin is not induced. Furthermore, p21 is not degraded when cells enter late differentiation stage.
To further validate that the contribution caspase-8 to the expression of keratinocyte differentiation markers occurs in a cell-autonomous manner, caspase-8 is reconstituted in the Casp-8fl/−K5-Cre kerartinocytes. In cultured Casp-8fl/−K5-Cre kertinocytes the expression of wild type caspase-8 is reinstituted using a lenti-virus expression vector and the ability to express the differentiation markers in response to calcium up-shift is regained. No such response to calcium up-shift is observed when the cells are transfected with an enzymatically inactive caspase-8 mutant (Carp-8-C362S). Moreover, expression of this mutant in keratinocytes derived from wild-type mice arrest the expression of the differentiation markers in them. Similar inhibition of differentiation marker expression is observed when keratinocytes derived from wild-type mice are transfected with a caspase-8 inhibitory protein or are treated with an agent capable of inhibiting caspase-8 activation. These results confirm that caspase-8 plays a cell-autonomous role in skin keratinocyte differentiation and indicates that this role depends on the enzymatic function of caspase-8.
A mouse oligo microarray Gene kit (Catalog 60-mer Oligo) purchased from Agilent Technologies was used following the manufacturer's instructions with RNA samples from skin of the Casp-8fl/−K5-Cre and from their F/+ littermates at three days after birth (P3). We found that the following genes with known pro-inflammatory functions were significantly upregulated in skin of Cre caspase-8fl/− mice: ISG15 (G1p2), Cxcl10, 9230117N10Rik (IL33)-human orthologue is called C90rf26, IL-19, Sprr2f, S100a9, IL-6, MMP13, Ccl3, and IL1b. The differential pattern of expression in samples of skin from the Casp-8fl/−K5-Cre mice shows predominant upregulation of type TH2 cytokines.
It was also found that two cDNAS of unknown function, 9230117E20Rik (SEQ ID NO: 2), and 2010002N04Rik (SEQ ID NO: 3) were significantly upregulated in the Casp-8fl/−K5-Cre mice (Table 1).
The differential pattern of gene regulation found in the gene array analysis of the preceding Example was further evaluated by real time PCR. For this purpose, skin was removed from wild type mice, Casp-8fl/−K5-Cre mice, or the double knockout TNF−/−Casp-8fl/−K5-Cre mice at different times after birth. Caspase-8-defficient mice were tested as follows: a day before birth (D−1), at the day of birth (P0), one day after birth (P1), two days after birth (P2), three days after birth (P3), and five days after birth (P5). Skin removed from mice was incubated for 2-3 seconds at 65° C. to separate epidermis and dermis. The sample of epidermis and dermis was converted into powder (with the aid of a mortar and pestle) and the powder was used as the starting material for the isolation of RNA with the Rneasy Kit of Quiagen, used following the manufacturer's instructions. RNA isolated from each skin sample removed from wild type mice, Casp-8fl/−K5-Cre mice, or the double knockout TNF−/−Casp-8fl/−K5-Cre mice at different times after birth was subjected to real time PCR using specific primers for genes which were found to be upregulated by the array technology.
All PCR reactions were carried out on Applied Biosystems 7500 Real-Time PCR System using proprietary TaqMan Gene Expression Assays obtained commercially and according to the manufacturer (Applied Biosystems) instructions.
The mRNA level found for each specific gene by PCR was normalized with the mRNA level of the control gene beta-actin (ACTB) tested in the same PCR reaction. mRNA upregulation of a specific gene at a given developmental stage after birth in 8fl/−K5-Cre mice or the double knockout TNF−/−Casp-8fl/−K5-Cre mice was calculated as the ratio of normalized mRNA of 8fl/−K5-Cre mice or the double knockout TNF−/−Casp-8fl/−K5-Cre mice and normalized mRNA of wild type found at the same developmental stage after birth by the delta Ct-method (Livak and Scmittgen, 2001). The ratios obtained were log 2-transformed and ordered according to increasing consistency of up-regulation of expression changes as shown in the heatmap of
The results show that out of the 22 double knockout TNF−/−Casp-8fl/−K5-Cre mice tested 11 showed significant upregulation of Isg15 (G1p2), 13 of CXC110, 13 of 9230117N10Rik (IL33), 16 of IL-19, 11 of 2010002N04Rik (SEQ ID NO: 3), 16 of Sprr2f, 16 of S100a9, 16 of IL-6, 6 of 9230117E20Rik (SEQ ID NO: 2), 12 of MMP13, 15 of Ccl3, and 11 of IL1b gene.
As mentioned, the skin pathology develops at day 3 after birth in the neck and the head area and gradually spreads to the whole body. We found by RT-PCR the same pattern of differential expression in samples from normal skin and skin showing pathology of the same P3 8fl/−K5-Cre mice (not shown).
The results obtained by RT-PCR analysis confirmed that genes having pro-inflammatory functions and genes encoding type TH2 cytokines such as IL-19 are significantly upregulated in samples of skin from Casp-8fl/−K5-Cre mice, that the same pattern of upregulation can be detected before the pathology develops, and that TNF has no principal effect on skin pathology, it only serves to amplify and expedite its development.
The effect of caspase-8 deficiency on the skin was further evaluated by in situ hybridization with a probe for s100a9 (see below), a chemokine found to be up regulated in the gene array analysis and in RT-PCR analysis of samples of skin from Casp-8fl/−K5-Cre mice. For this purpose, paraffinized skin sections of 6 um thick from P7 wild type mice or P7 Casp-8fl/−K5-Cre mice were applied in slides. After deparaffinization (by subjecting to xylene 10 minutes 2 times, 100% ethanol 2 times for 2 minutes of each, 95% ethanol 2 minutes, 70% ethanol 2 minutes, 50% ethanol 2 minutes), slides were treated with proteinase K (10 ug/ml) for 10-20 min, fixed with 4% paraformaldehyde (PFA) and acetylated (employing 2.2 ml triethanolamine in 200 ml DEPC treated water with 750 ul of acetic anhydride for 5 minutes). Then slides were then hybridized with anti-sense or sense (control) probe for overnight incubation at 65° C. and 24 hours latter, the slides were washed with several different concentrations of SSC buffer [a. 5×SSC with 10 mM DTT 30 min at 65 C, b. 2×SSC with 10 mM DTT and 50% formamide 30 min at 65 C, c. 2×SSC 5 min×3 at 37 C, d. RNase A (10 ug/ml) in 0.4M NaCl, 0.01M Tris-HCl pH7.5, 0.005M EDTA 30 min at 37 C, and e. 2×SSC 15 min at 37 C, f. 0.1×SSC 15 min at 37 C] and incubated with anti-DIG antibody for 2 hr at room temperature. After that, the slides were developed by a colorimetric substrate (Anti-Digoxigenin-Alkaline Phosphatase, Roche) for few hours to several days.
The results of in situ hybridization with anti-sense (SEQ ID NO: 35) and sense (control) probes from s100a9 applied to skin of P7 wild type mice or of P7 Casp-8fl/−K5-Cre mice are summarized in
For Western blot analysis, samples of whole skin, epidermis and dermis, of P4 Casp-8fl/−K5-Cre mice or P4 wild type mice was isolated. Each sample was crushed with pestle and mortar and cells in the tissue were lysed by incubation with 10 ul of RIPA buffer for 1 mg of tissue (RIPA buffer, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA pH8, 0.1% SDS, 1% NP-40) was used for extraction of protein. Next, the sample of tissue lysate was incubated for 10 min at 0° C., sample buffer added, and incubated at 100° C. for 5 min. Samples were span 13,00 rpm and the supernatant resolved on 10% SDS polyacryamide gel and blotted onto nitrocellulose membranes.
The nitrocellulose membranes containing the resolved skin proteins were probed with antibodies specific for Stat-1 and Stat-3. Stat-1 and Stat-3 are transcription factors that became active upon phosphorylation, by protein kinases that are induced by IL-6, translocate to the nucleus and are used as markers for skin inflammatory pathology. The results obtained with the Stat specific antibodies show that only in the samples of skin epidermis of Casp-8fl/−K5-Cre mice a band corresponding to phosphorylated Stat-1 or phosphorylated Stat-3 is detected (
Since pro-Caspase-14 is known to be constitutively processed into active caspase-14 in the skin epidermis, it was of interest to test whether the resulting inflammatory pathology induced by caspase-8 deficiency involves regulation of pro-caspase-14 processing in this tissue. For this purpose, the nitrocellulose membranes containing the resolved skin proteins were probed with antibodies specific for caspase-14. The results summarized on
S100A8 is a chemokine expressed by macrophages. S100A8 is known to form an heterodimer with S100A9, a gene that we previously found to be upregulated in the skin of Casp-8fl/−K5-Cre mice by gene array and in the epidermis of Casp-8fl/−K5-Cre mice by RT-PCR analysis. The presence of S100A8 protein was analyzed by Western blot hybridization in samples of whole skin, dermis or epidermis isolated from Casp-8fl/−K5-Cre or wild type mice. The results summarized in
IL-1α and IL-1μ were found to be upregulated in the skin of Casp-8fl/−K5-Cre mice by gene array and in the epidermis of Casp-8fl/−K5-Cre mice by RT-PCR analysis. We further explored the role of IL-1 α and IL-1 β in the skin inflammatory process, which occurs as a result of caspase-8 deficiency in the keratinocytes. Double knock out mice in either the IL-1 α gene or the IL-1 β gene and in the Casp-8fl/−K5-Cre were obtained by crossing Casp-8fl/−K5-Cre mice with the knock out mice in either the IL-1 α gene or the IL-1 β gene (Horai et al. 1998). The double knock out mice did not show a drastic delay of initiation of the skin pathology and survived only to day 8 or 9 as the Casp-8fl/−K5-Cre mice.
| Number | Date | Country | Kind |
|---|---|---|---|
| 171451 | Oct 2005 | IL | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12090478 | Apr 2008 | US |
| Child | 14791031 | US |
